Claude Schulman
Research Subjects
Research Interests
Claude Schulman has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
B. Tombal
2 shared publicationsJ. Irani
Urology Unit, University Hospital, Poitiers, France
2 shared publicationsA. Haese
University Medical Centre Eppendorf, Hamburg, Germany
1 shared publicationA. Stari
1 shared publicationA. de la Taille
Hôpital Henri Mondor, Créteil, France
1 shared publicationAbraham Morgentaler
Harvard Medical School
1 shared publication
Latest Publications
- Open Access
- 1 April 2016
- Published by Elsevier in European Urology
- Vol. 69 (4) , 720-727
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)
- 1 April 2016
- Published by Elsevier in European Urology
- Vol. 69 (4) , 720-727
Open AccessIntermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)
- 16 January 2013
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 22 (2) , 210-218
Access to information and expectations of treatment decisions for prostate cancer patients - results of a European survey
We surveyed patients in France, Germany, Italy, Spain and Poland to examine information requirements and expectations of patients with prostate cancer. Patients were identified via their healthcare teams or via existing databases and interviewed by telephone, or in face-to-face interviews (Italy). Survey questions were either multiple choice or rank-based, and additional information was available to assist patient comprehension. Overall, 80% of patients received information about prostate cancer at diagnosis and 76% rated their physician as the most useful information source. However, around a third of French and German patients did not receive any information about their condition at diagnosis, compared with 8%, 12% and 10% of Spanish, Italian and Polish patients, respectively. Most patients rated the information they received as ‘very informative’, but there were regional variations, with German patients being the least satisfied with the quality of information received. Despite receiving the least amount of information at diagnosis, more patients from France and Germany preferred to be involved in treatment decisions than patients from Spain, Italy and Poland. Results from this survey highlight important gaps in information provision for patients with prostate cancer in terms of information supplied and patient expectations regarding treatment decisions.
- 16 January 2013
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 22 (2) , 210-218
Access to information and expectations of treatment decisions for prostate cancer patients - results of a European survey
We surveyed patients in France, Germany, Italy, Spain and Poland to examine information requirements and expectations of patients with prostate cancer. Patients were identified via their healthcare teams or via existing databases and interviewed by telephone, or in face-to-face interviews (Italy). Survey questions were either multiple choice or rank-based, and additional information was available to assist patient comprehension. Overall, 80% of patients received information about prostate cancer at diagnosis and 76% rated their physician as the most useful information source. However, around a third of French and German patients did not receive any information about their condition at diagnosis, compared with 8%, 12% and 10% of Spanish, Italian and Polish patients, respectively. Most patients rated the information they received as ‘very informative’, but there were regional variations, with German patients being the least satisfied with the quality of information received. Despite receiving the least amount of information at diagnosis, more patients from France and Germany preferred to be involved in treatment decisions than patients from Spain, Italy and Poland. Results from this survey highlight important gaps in information provision for patients with prostate cancer in terms of information supplied and patient expectations regarding treatment decisions.
- 4 June 2012
- Published by Wiley in BJU International
- Vol. 109 (s6) , 13-21
Improving the management of patients with prostate cancer receiving long‐term androgen deprivation therapy
In many patients with prostate cancer, androgen deprivation therapy (ADT) is administered over prolonged periods of time. The benefits of long‐term ADT in patients with advanced disease are well established and, more recently, studies have shown that long‐term adjuvant ADT used in combination with radiotherapy improves survival in patients with earlier stages of disease. Nevertheless, clinicians should remain aware of the potential long‐term side effects of ADT and the strategies that can be used to manage or prevent long‐term complications. One such strategy is intermittent androgen deprivation (IAD), in which patients receive cycles of ADT, the duration of which is usually determined by PSA levels. Accumulating data indicate that this approach improves the tolerability of ADT (particularly sexual dysfunction) and patients' quality of life, without compromising clinical outcomes (progression and survival). Indeed, the latest European Association of Urology guidelines state that IAD should no longer be considered investigational. Nevertheless, some questions remain unanswered, including: who are the most suitable patients for IAD and what are the optimal PSA levels for stopping and restarting treatment? Osteoporosis (and the resultant increased risk of fractures) is a well‐recognized complication of long‐term ADT. Bone mineral density should be measured before and during long‐term ADT and patients advised to make appropriate lifestyle changes to help preserve bone health. Pharmacological intervention is also an option. Denosumab (an NF‐κB ligand inhibitor) significantly reduces ADT‐induced bone loss and the risk of fractures in patients with non‐metastatic disease. In those whose disease has metastasized, zoledronate and denosumab are licensed to prevent skeletal‐related events and a large randomized study has shown that denosumab is more effective than zoledronate in this setting.
- 4 June 2012
- Published by Wiley in BJU International
- Vol. 109 (s6) , 13-21
Improving the management of patients with prostate cancer receiving long‐term androgen deprivation therapy
In many patients with prostate cancer, androgen deprivation therapy (ADT) is administered over prolonged periods of time. The benefits of long‐term ADT in patients with advanced disease are well established and, more recently, studies have shown that long‐term adjuvant ADT used in combination with radiotherapy improves survival in patients with earlier stages of disease. Nevertheless, clinicians should remain aware of the potential long‐term side effects of ADT and the strategies that can be used to manage or prevent long‐term complications. One such strategy is intermittent androgen deprivation (IAD), in which patients receive cycles of ADT, the duration of which is usually determined by PSA levels. Accumulating data indicate that this approach improves the tolerability of ADT (particularly sexual dysfunction) and patients' quality of life, without compromising clinical outcomes (progression and survival). Indeed, the latest European Association of Urology guidelines state that IAD should no longer be considered investigational. Nevertheless, some questions remain unanswered, including: who are the most suitable patients for IAD and what are the optimal PSA levels for stopping and restarting treatment? Osteoporosis (and the resultant increased risk of fractures) is a well‐recognized complication of long‐term ADT. Bone mineral density should be measured before and during long‐term ADT and patients advised to make appropriate lifestyle changes to help preserve bone health. Pharmacological intervention is also an option. Denosumab (an NF‐κB ligand inhibitor) significantly reduces ADT‐induced bone loss and the risk of fractures in patients with non‐metastatic disease. In those whose disease has metastasized, zoledronate and denosumab are licensed to prevent skeletal‐related events and a large randomized study has shown that denosumab is more effective than zoledronate in this setting.
- 31 July 2011
- Published by Elsevier in European Urology
- Vol. 60 (1) , 194
Corrigendum to “Reply to Ruth E. Langley, Patricia Price and Paul D. Abel's Letter to the Editor re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675–91” [Eur Urol 2011;59:e26]
- 31 July 2011
- Published by Elsevier in European Urology
- Vol. 60 (1) , 194
Corrigendum to “Reply to Ruth E. Langley, Patricia Price and Paul D. Abel's Letter to the Editor re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675–91” [Eur Urol 2011;59:e26]
- 18 January 2011
- Published by Elsevier in European Urology
- Vol. 59 (4) , e26
Reply to Ruth E. Langley, Patricia Price and Paul D. Abel’s Letter to the Editor re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675–91
- 18 January 2011
- Published by Elsevier in European Urology
- Vol. 59 (4) , e26
Reply to Ruth E. Langley, Patricia Price and Paul D. Abel’s Letter to the Editor re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675–91
- 12 August 2009
- Published by Elsevier in European Urology Supplements
- Vol. 8 (12) , 852-856
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
- 12 August 2009
- Published by Elsevier in European Urology Supplements
- Vol. 8 (12) , 852-856
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?